34. Трофимова Т.Н. Нейрорадиология: Оценка эффективности хирургии и комбинированной терапии глиом. Практическая онкология 2016;17(1):32–40.
35. Lee N.Y., Lu J.J., eds. Target volume delineation and field setup: a practical guide for conformal and intensity-modulated radiation therapy. Springer-Verlag; 2013. DOI: 10.1007/174_2014_1005
36. Goldbrunner R., Minniti G., Preusser M. EANO guidelines for diagnosis and treatment of meningiomas. Lancet Oncol 2016;17(9):e383–91.
37. Галкин М.В. Стереотаксическая лучевая терапия в лечении менингиом медиальных отделов средней черепной ямки. Дис. … канд. мед. наук. М.: 2011.
38. Когония Л.М., Волошин А.Г., Новиков Г.А., Сидоров А.В. Практические рекомендации по лечению хронического болевого синдрома у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018;8:617–35.
39. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Adult Cancer Pain. Version 3, 2019.
40. Сомонова О.В., Антух Э.А., Елизарова А.Л., Матвеева И.И., Сельчук В.Ю., Черкасов В.А. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018;8:604–9.
41. NCCN Clinical Practice Guidelines in Oncology ((NCCN Guidelines®). Cancer Associated Venous Thromboembolic Disease. Version 3, 2019
42. Sourati A., Ameri A. Acute Side Effects of Radiation Therapy: A Guide To Management. Springer, 2017.
43. Vargo M. Brain Tumor Rehabilitation. Am J Phys Med Rehabil 2011;90(5 Suppl 1):S50–62.
44. Харченко В.П., Паньшин Г.А., Сотников В.М., Измайлов Т.Р. Новые режимы лучевой терапии злокачественных опухолей головного мозга. Разрешение ФС №2009/147 от 11.06.2009 г.
45. Wick W., et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707–15.
46. Malmström A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13(9):916–26.
47. Louis, D.N., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–51. DOI: 10.1093/neuonc/noab106
48. She L, Su L, Liu C. Bevacizumab combined with re-irradiation in recurrent glioblastoma. Front Oncol. 2022 Aug 4;12:961014. doi: 10.3389/fonc.2022.961014. PMID: 36046037; PMCID: PMC9423039.
49. Rutkowski, M.J., et al. Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series. World Neurosurg 2016;95 368–74. doi:10.1016/j.wneu.2016.07.068
50. Weller M., Pfister S.M., Wick W., Hegi M.E., Reifenberger G., Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013;14(9):e370–9. DOI: 10.1016/S1470-2045(13)70168-2
51. Dubbink H.J., Atmodimedjo P.N., Kros J.M., French P.J., Sanson M., Idbaih, A., et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Оncol 2016;18(3):388–400. DOI: 10.1093/neuonc/nov182
52. Hartmann C., Hentschel B., Wick W., Capper D., Felsberg J., Simon M., et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta neuropathol 2010;120(6):707–18. DOI: 10.1007/s00401-010-0781-z
53. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathol 2009;118(4):469–74. DOI: 10.1007/s00401-009-0561-9
54. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343(19):1350–4. DOI: 10.1056/NEJM200011093431901
55. Hegi M.E., Diserens A.-C., Gorlia T., Hamou M.-F., de Tribole N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997–1003. DOI: 10.1056/NEJMoa043331
56. Sahm F., Reuss D., Koelsche C., Capper D., Schittenhelm J., Heim S., et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta neuropathol 2014;128(4):551–9. DOI: 10.1007/s00401-014-1326-7
57. van den Bent MJ., Brandes A.A., Taphoorn M.J.B., Kros J.M., Kouwenhoven M.C.M., Delattre J.-Y., et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31(3):344–50. DOI: 10.1200/JCO.2012.43.2229
58. Cairncross G., Wang M., Shaw E., Jenkins R., Brachman D., Buckner J., et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31(3):337–43. DOI: 10.1200/JCO.2012.43.2674
59. Reuss D.E., Sahm F., Schrimpf D., Wiestler B., Capper D., Koelsche C., et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta neuropathol 2015;129(1):133–46. DOI: 10.1007/s00401-014-1370-3
60. Nikiforova M.N., Wald A.I., Melan M.A., Roy S., Zhong S., Hamilton R.L., et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Оncol 2016;18(3):379–87. DOI: 10.1093/neuonc/nov289